Amgen Reports Phase 3 DeLLphi-L301 Results for Imdelltra in Small Cell Lung Cancer

Amgen today announced results from the Phase 3 DeLLphi-L301 trial evaluating tarlatamab (Imdelltra) versus topotecan or amrubicin in patients with relapsed small cell lung cancer. The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival for tarlatamab. The median OS was 14.3 months for tarlatamab versus 8.9 months for chemotherapy. These results support tarlatamab as a new standard of care in relapsed SCLC and may support conversion to full approval.